COMPOSITION COMPRISING COAGULATION FACTOR VIII FORMULATION, PROCESS FOR ITS PREPARATION AND USE OF A SURFACTANT AS STABILIZER

Abstract: The present invention relates to novel composition comprising coagulation factor VIII and a non-ionic surfactant such as block copolymers, e.g. polyoxamers or polyoxyethylene (20) sorbitan fatty acid esters e.g. polysorbate 20 or polysorbate 80 as stabilizer. The composition can also comprise sodium chloride, calcium chloride, L-histidine and/or sugars or sugar alcohols. The invention also relates to the use of a non-ionic surfactant as stabilizer for a composition comprising coagulation factor VIII.

Description: COMPOSΓΠON COMPRISING COAGULAΉON FACTOR vm FORMULATION, PROCESS FOR ITS PREPARAΉON AND USE OF A SURFACTANT AS STABILIZER . The present invention relates to a novel formulation comprising coagulation factor Vπi and a non-ionic surfactant such as block co-polymers, e.g. polyoxamers or polyoxyethylene (20) sorbitan fatty acid esters e.g. polysorbate 20 or polysorbate 80. The composition can also comprise sodium chloride, calcium chloride, L-histidine and/or sugars and/or sugar alcohols. Haemophilia is an inherited disease which has been known for centuries but it is only within the last three decades that it has been possible to differentiate between the various forms; haemophilia A, haemophilia B and haemophilia C. Haemophilia A is the most frequent form. It affects only males with an incidence of one or two individuals per 10 000 live-born males. The disease is caused by strongly decreased level or absence of biologically active coagulation factor NTH (antihaemophilic factor) which is a protein normally present in plasma. The clinical manifestation of haemophilia A is a strong bleeding tendency and before treatment with factor NTH concentrates was introduced, the mean age of those patients was less than 20 years. Concentrates of factor VDI obtained from plasma have been available for about three decades. This has improved the situation for treatment of haemophilia patients considerably and given them possibility to live a normal life. Therapeutic factor VHI concentrates have until now been prepared by fractionation of plasma. However, there are now methods available for production of factor NTJI in cell culture using recombinant DΝA techniques as reported in e.g. J Gitschier et al. Nature 312, 330-37 984 and EP 160457. Factor VIII concentrates derived from human plasma contain several fragmented fully active factor VTH forms (Andersson et al, Proc. Natl. Acad. Sci. USA, Vol 83,2979-83, May 1986). The smallest active form has a molecular mass of 170 kDa and consists of two chains of 90 kDa and 80 kDa held together by a metal ion bridge. Reference is here made to EP 197901. Kabi Pharmacia has developed a recombinant factor VIII product which corresponds to the 170 kDa plasma factor Vrπ form in therapeutic factor Viπ concentrates. The truncated recombinant factor Vm. molecule is termed r- Vrπ SQ and is produced by Chinese Hamster Ovary (CHO) cells in a cell culture process in serum free medium at finite passage. The specific activity of r-Vm SQ could be more than 12 000 IU/mg protein and preferably more than 14 000 IU/ mg. Activity of about 15 000 IU/mg has been measured. About 10 000 IU VTI C per mg protein has earlier been known for our r-VDI SQ. Recombinant factor VIII SQ is indicated for treatment of classical haemophilia. The dosage is similar to the dosage of the plasma factor Viπ concentrates. Due to the high concentration now obtainable only small volumes are needed for injection. The structure and biochemistry of recombinant factor Vffl-products in general have been described by Kaufman Tibtech, Vol 9,1991 and Hematology, 63, 155-65, 1991. The structure and biochemistry of r-Vm SQ have been described in WO 91/09122. The stability of proteins is generally a problem in pharmaceutical industry. It has often been solved by drying of the protein in different drying processes, such as freeze drying. The protein has thereafter been distributed and stored in dried form. The solution before drying or freeze-drying, the dried material and the reconstituted product should all be stable, so that not too much activity is lost during the drying process, the storage or during handling. Factor VIII which has been fractionated from plasma is normally sold as lyophilized powder which should be reconstituted with water. A formulation with a low amount of protein will generally loose activity during purification, sterile manufacturing, in the package and during the administration. This problem is usually solved by the addition of human albumin which reduces the activity loss of the active protein considerably. Human albumin functions as a general stabilizer during purification, sterile manufacturing and freeze-drying (see review by Wang et al., J. of Parenteral Sά. and Tech. Vol 42, Number 2S, supplement. 1988). Human albumin is also a good cake-former in a formulation for freeze-drying. The use of albumin for stabilization of factor VTJI is known and is currently us* » d in all highly purified factor VTJI products on the market. However, it is not desirable to add human albumin to a therapeutic protein manufactured by recombinant DNA technology. In addition, the use of human albumin as a formulation exάpient often limits the use of many of the most powerful and sensitive analytical methods for protein characterization. There is a need for albumin free formulations containing factor VTH and especially recombinant factor VD3 which are stable during drying or freeze- drying, in solution and as a solution after reconstitution. Several solutions have been proposed for the stabilization of different proteins: EP 35 204 (Cutter) discloses a method for imparting thermal stability to a protein composition in the presence of a polyol. EP 381 345 (Corint) discloses an aqeous liquid of a peptide, desmopressin, in the presence of carboxymethylcellulose. In WO 89/09614 (Genentech), a stabilized formulation of human growth hormone comprising glycine, mannitol and a buffer is disclosed and in a preferred embodiment a non-ionic surfactant such as polysorbate 80 is added. The non-ionic surfactant is adde; - reduced aggregation and denaturation. The foπr ..tion has an inc ■ . ■ , stability in a lyophilized formulation and upon re ; restitution. EP 268 110 (Cetus) discloses a solution comprising a particular protein, interleukin-2, which is dissolved in an inert carrier medium comprising a non-ionic polymeric detergent as a solubilizer/stabilizer. The preferred detergents are octylphenoxy pol ethoxy ethanol compounds, polyethylene glycol monostearate compounds and polyethylene sorbitan fatty acid esters. US 4 783 441 (Hoechst)discloses an aqueous solution comprising a protein, such as insulin and a surface active substance. US 4 165 370 (Coval) discloses a gamma globulin solution and a process for the preparation thereof. The solutions contains polyethylene glycol (PEG). A non-ionic surfactant can be added to the solution. In EP 77 870 (Green Cross) the addition of amino acids, monosaccarides, oligosaccarides or sugar alcohols or hydrocarbon carboxylic acid to improve stability of a solution containing factor NTH is disclosed and the addition of sugar alcohol or disaccarides to an aqueous solution of factor VIII for increasing stability during heat treatment has been disclosed in EP 117 064 (Green Cross). WO 91/10439 (Octopharma) claims stable injectable solution of factor VTJI or factor IX which comprises a disaccaride, preferably saccarose and one or more amino acids. EP 315 968 and EP 314 095 (Rorer) claim stable formulations of factor Viπ with different ionic strength. Proteins are different with regard to physico-chemical properties. When preparing a pharmaceutical preparation which should be physico-chemical acceptable, and stable for a long time, consideration can not only be taken to the physiological properties of the protein but also other aspects must be considered such as the industrial manufacture, easy handling for the patient and safety for the patient. The results of these aspects are not predictable when testing different formulations and there often is a unique solution for each protein. In plasma circulating factor VTJI is stabilized by association with its carrier protein, the von Willebrand factor (vWF). In plasma and also in conventional intermediate purity factor VTTI concentrates the ratio vWF to factor VTJI is at least 50:1 on a weight basis. In very high purity factor VTJI concentrates, with a specific activity of more than 2 000 IU per mg protein, the ratio vWF to factor VUl is about 1:1 (w/w) and essentially all factor VTII is bound to vWF. Despite this stabilization further protection by the addition of albumin is required in order to achieve an acceptable stability during lyophilization and storage. All super pure preparations on the market are stabilized with albumin (human serum albumin). There is a now a demand for injectable factor Vm without albumin and containing a minimum of additives. We have now developed a new formulation which solves the above mentioned problems for factor Vm. To our great surprise we have found that factor VTII, which is a very sensitive protein, can be stabilized without albumin, when a non-ionic surfactant is added. Thus the present invention relates to a composition comprising a coagulation factor VTII and a non-ionic surfactant as stabilizer. Our factor VD3 is highly purified, i.e. has a specific activity of more man 5000 IU/mg protein, and the composition is stabilized without the addition of albumin. When factor VTJI is recombinant it can be either in its full-length form or as a deletion derivative such as SQ derivative. The amount of factor Vm is from 10 to 100 000 IU/ml, preferably 50 to 10 000 IU/ml. The non-ionic surfactant is preferably chosen from block co-polymers such as a poloxamer or polyoxyethylene (20) fatty acid ester, such as polysorbate 20 or polysorbate 80. Tween 80® has been used as polysorbate 80. The non-ionic surfactant should be present in an amount above the critical micelle concentration (CMC). See Wan and Lee, Journal of Pharm Sci, 63, 136, 1974. The polyoxyethylene (20) fatty ac J esteris thus preferably_in an amount of at least 0.01 mg/ml. The amount could e.g. be between 0.02 and 1 mg/ml. The composition can also comprise sodium or potassium chloride, preferably in an amount of more than 0.1 M. The composition comprises preferably a calcium salt such as calcium chloride or calcium gluconate preferably in an amount of more than 0.5 mM and an amino acid such as L-histidine in an amount of more than 1 mM. The amount could e.g. be chosen between 0.05 and 500 mM. Mono-or disaccarides such as sucrose or sugar alcohols could be added e.g. in an amount of 1 to 300 mg/ml. The composition comprises preferably L-histidine and sucrose. The ratio sodium chloride to L-histidine in the composition is preferably more than 1:1. The composition could comprise i) 10-100000 IU/ml of recombinant factor Vm ii) at least 0.01 mg/ml. of a polyoxyethylene (20) fatty acid ester iii) sodium chloride, preferably in an amount of more than 0.1 M. iv) calcium salt such as calcium chloride or calcium gluconate preferably in an amount of more than 0.5 mM. v) an amino acid such as L-histidine in an amount of more than 1 mM. To this composition could mono-or disaccarides or sugar alcohols, preferably sucrose be added. The composition could be in a dried form, preferably lyophilized or in aqeous solution before or after drying. The dried product is reconstituted with sterile water for injection or a buffer solution. The claimed composition can also be a stable aqeous solution ready for use. The invention also relates ot compositions in which the specific activity of r- Vrπ SQ is more than 12000 IU / mg protein , preferably more than 14000 IU / mg. The claimed composition can be prepared by mixing factor Vm with a non- ionic surfactant in an aqeous solution, preferably together with an amino acid such as L-histidine, sodium salt, sucrose and a calcium salt or by eluating factor VIQ from the last purification step with a buffer containing a non-ionic surfactant in an aqeous solution, preferably together with an amino acid such as L-histidine, sodium salt, sucrose and a calcium salt. The invention also relates to the use of a non ion surfactant preferably chosen from block co-polymers, preferably a poloxa.*: ter or polyoxyethylene (20) fatty acid ester, preferably polysorbate 20 or polysorbate 80, as stabilizer for a composition comprising coagulation factor Vm. An amino acid is used to buffer the system and it protects also the protein in the amorphous phase. A suitable buffer could be L-histidine, lysine and/or arginine. L-Histidine has primarily been chosen because of the good buffer capacity of L-histidine around pH 7. Sucrose or sugar alcohol can also be added for the protection of the protein. Calcium (or divalent metal ions), here added as calcium chloride (CaCl2) but other salts such as calcium gluconate, calcium glubionate or calcium gluceptate can also be used, is necessary for the maintenance of the association of factor Vm hea and light chain. The data presented in the examples indicate that r-VT-H SQ is stable for at least 12 months when stored at 5±3°C. The following examples illustrate the invention and show stability data for different formulations, all falling under the patent protection, a protection which is not limited to these examples. The following figures are illustrating the invention: Figure 1 HPLC gelfiltration, Example 10A, stored 5 months at 25°C. Figure 2 HPLC gelfiltration, Example 10B, stored 5 months at 30°C. SUBSTITUTE SHEET EXPERIMENTAL Material and methods The production of recombinant factor VIH SQ (r-Vπi SQ) was essentially performed as described in patent WO 91/09122, example 1-3. A DHFR deficient CHO celline (DG44N.Y.) was electroporated with an expression vector containing the r-VHI SQ gene and an expression vector containing the dihydrofolate-reductase gene. Following selection on selective media surviving colonies were amplified through growth in stepwise increasing amounts of methotrexate. Supernatant from the resulting colonies were individually screened for VHLC activity. A production done was chosen and this was subsequently adapted to serum free suspension growth in a defined medium and finally a large scale fermentation process was developed. Supemantant is collected after certain time periods and further purified as described below. The clarified conditioned medium was pH adjusted and applied to a S- Sepharose FF column. After washing, factor VIH was eluated with a salt buffer containing 5 mM CaCl2,- Immunoadsorption was carried out on an immunoaffinity resin where the ligand was a monoclonal antibody (8A4) directed towards the heavy chain of Factor VD-I. Before loading to the column the S-eluate was treated with 0,3 % TNBP and 1 % Octoxynol 9. The column was equilibrated, washed and factor VHI was eluated with a buffer containing 0,05 M CaCl2 and 50 % ethylene glycol. The mAb-eluate was loaded on a Q-Sepharose FF column, equilibrated with the dution buffer in the immunoaffinity step. After washing, factor VHI was eluated with 0,05 M L-histidine, 4 mM CaCl2, 0,6 M NaCl, pH 6,8. The Q-eluate was applied to a gel filtration column (Superdex 200 p.g.). Equilibration and elution was carried out with a formulation containing sodium chloride, L-histidine, caldum chloride and polysorbate 80. The protein peak was collected and the solution was formulated before freeze drying. The Vπi:C activity and the concentration of the inactive components were adjusted by diluting with an appropriate buffer. The solution was then sterile filtered (0,22 μm), dispensed and freeze-dried. Samples from each composition were frozen and stored at - 70 °C. These samples were thawed and used as references during the assay of VQLC. The coagulant activity VHLC was assessed by a chromogenic substrate assay (Coatest Factor VHI, Chromogenix AB, Molndal, Sweden). Activated factor X (Xa) is generated via the intrinsic pathway where factor VHLC acts as cofactor. Factor Xa is then determined by the use of a synthetic chromogenic substrate, S-2222 in the presence of a thrombin inhibitor 1-2581 to prevent hydrolysis of the substrate by thrombin. The reaction is stopped with acid, and the Vπi:C, which is proportional to the release of pNA (para- nitroaniline), is determined photometrically at 450 nm against a reagent blank. The unit of factor VHLC is expressed in international units (IU) as defined by the current International Concentrate Standard (IS) established by WHO. The recovery of VHLC is calculated as the percentage of VULC in the reconstituted solution divided by the VHLC in the frozen and thawed solution for freeze-drying with appropriate adjustment for dilutions. Soluble aggregates were determined by gel filtration. A prepacked Superdex 200 HR 10/30 column (Pharmacia) was used with a fluorescence detector (exitation wavelength 280 nm), emission wavelength 340 nm). The reconstituted preparation were analysed. Evaluation of results from gelfiltration was done by visual examination of the chromatograms, or by integration of the peak areas if aggregates were found. Recovery over freeze drying is expressed in % yield of frozen reference. Example 1. Comparison between albumin and non-ionic surfadant. Recombinant fador VHI was prepared according to the method described under Experimental. Two ml of the solution was lyophilized and thereafter reconstituted in an amount of 5 ml of sterile water for injections. This example shows that there was no difference in the recovery of factor VHI:C when the non ionic surfactant or albumin was used. Example 2, Comparison between different strengths of non ionic surfactant Recombinant factor VIH was prepared according to the method described under Experimental. Two ml of the solution was lyophilized and thereafter reconstituted in an amount of 2 ml of sterile water for injections. The compositions were the following 2 A 2B 2 C * stored as reconstituted solution at ambient temperature It is here clearly shown the surprisingly good stabilizing effed on factor VEQ when a non ionic surfadant is used. Example 3 , Variation of non-ionic surfadant concentration. Recombinant fador VIH was prepared according to the method described under Experimental. Two ml of the solution was lyophilized and thereafter reconstituted in an amount of 5 ml of sterile water for injections. Results from this example indicate that the recovery of factor VIH (VHLC) was very high after reconstitution and good for all concentrations of polysorbate 80 used. Example 4. Variation of sodium chloride concentration Recombinant factor VIH was prepared according to the method described under Experimental. Two ml of the solution was lyophilized, stored at different temperatures for up to 6 months (mon) and thereafter reconstituted in an amount of 5 ml of sterile water for injections. 0,3 or 0,6 M sodium chloride showed very good stability. Both formulations were stable for 6 months at 37°C. Example 5. Variation of L-Histidine concentration Recombinant fador VHI was prepared according to the method described under Experimental. 2,2 ml of the solution was lyophilized, stored at different temperatures for up to 3 months (mon) and thereafter reconstituted in an amount of 5 ml of sterile water for injections. 5B 59 0.31 3,7 0.091 0.364 84 76 74 85 48 73 48 This example shows that these different amounts of L-histidine does not effed the stability. Example 6 Recombinant factor VHI was prepared according to the method described under Experimental. 6B 65 0.3 4 0.1 0.025 These solutions were freezed/thawed 1, 5 and 10 times and the recovery was the following: cold 1 freezing 5 10 These studies showed that VHLC was stable after repeated freeze-thawing and that PEG-4000, which is thought to act as cryoprotectant, is not necessary in this formulation. Example 7. Variation of pH Recombinant fador VHI was prepared according to the method described under Experimental. 2,2 ml of the solution was lyophilized and thereafter reconstituted in an amount of 5 ml of sterile water for injections. *stored as reconstituted solution at ambient temperature This example shows that a pH is of no significant importance between 6.0 and 7.5 approx. Example 8 Addition of sucrose Recombinant factor VTH was prepared according to the method described under Experimental. 2,2 ml of the solution was lyophilized and thereafter reconstituted in an amount of 5 ml of sterile water for injections. L-Histidine, mM Sodium chloride. M Caldum chloride, mM Sucrose, mM Polysorbate 80, % Sucrose was added to the solution B after the final purification step before lyophilization. The recovery after freeze-drying was 76 % for A and 87 % for B. The same activity was found 4 hours after reconstitution stored at room temperature. This study indicated that the addition of sucrose is favourable for the recovery of VHLC over freeze-drying. Example 9 . Variation of caldum salt Recombinant fador VHI was prepared according to the method described under Experimental. Two ml of the solution was lyophilized and thereafter reconstituted in an amount of 5 ml of sterile water for injections. *stored as reconstituted solution at ambient temperature This example shows that CaCl2 can be substituted by Caldum gluconate. Example 10 Recombinant fador VHI was prepared according to the method described under Experimental. 2,2 ml of the solution was lyophilized and thereafter reconstituted in an amount of 5 ml of sterile water for injections. VHLC per vial in reconstituted preparation was about 1000 IU. These formulations were studied by gelfiltration after 5 months 'storage at 25°C and 30°C, respectively and the results are shown in figures 1 and 2. The only peaks to be seen is the peak at 42, indicating factor VHLC and the peak at 70 which is histidine. Aggregates is to be found earlier than 40. From figure 1 it can be seen that no detedable amount of aggregates was found after 5 months at 25° C for 10 A. Figure 2 shows a small amount of aggregates which is less than 2 % after 5 months at 30°C for 10B . SUBSTITUTE SHEET Example 11 Recombinant factor VHI was prepared according to the method described under Experimental. 2,2 ml of the solution was lyophilized and thereafter reconstituted in an amount of 5 ml of sterile water for injections. VHLC per vial in reconstituted preparation was about 500 IU. 11B 58 0.31 3.7 0.025 105 103 101 93 87 79 89 Both formulations showed good stability. These formulations were studied by gelfiltration and the results were similar as shown in Figures 1 and 2. No aggregation was formed when the formulations had been stored for 5 months at 25°C and 30°C, respectively. Example 12 Recombinant fador VIH was prepared according to the method described under Experimental. 2 ml of the solution was lyophilized, stored at different temperatures for up to 3 months (mon) and thereafter reconstituted in an amount of 4 ml of sterile water for injections. VHLC per vial in reconstituted preparation was about 500 IU. An acceptable stability was achieved after five months at 7°C.

Claims: CLAIMS 1. A composition comprising coagulation factor VQI and a non-ionic surfadant as stabilizer. 2. A composition according to daim 1 in which factor VHI is highly purified and stable without the addition of albumin. 3. A composition according to daim 1 or 2 in which factor VHI is full-length or a deletion derivative of recombinant fador VHI. 4. Composition according to any of claims 1-3 in which the amount of fador VIH is 10 to 100 000 IU id, pr srably 50 to 10 000 IU/ml. 5. Composition according to any of claims 1-4 in which the non-ionic surfactant is present in an amount above the critical micelle concentration. 6. Composition according to any of claims 1-5 in which the non-ionic surfadant is chosen from block co-polymers, preferably a poloxamer or polyoxyethylene (20) fatty acid ester, preferably polysorbate 20 or polysorbate 80. 7. Composition according to daim 6 in which the polyoxyethylene (20) fatty acid ester is in an amount of at least 0.01 mg/ml. 8. Composition according to any of daims 1-7 which comprises sodium or potassium chloride, preferably in an amount of more than 0.1 M. 9. Composition according to any of claims 1-8 which comprises caldun. salt such as calcium chloride or calcium gluconate preferably in an amount of more than 0.5 mM. 10. Composition according to any of daims 1-9 which comprises an amino acid such as L-histidine in an amount of more than 1 mM. 11. Composition according to any of daims 1-10 which comprises mono-or disaccarides, prferably sucrose or sugar alcohols. 12. Composition according to any of claims 10-11 which comprises L- histidine and sucrose. 13. Composition according to claim 8 and 10 in which the ratio sodium chloride to L-histidine is more than 1:1. 14. Composition according to any of daims 1-13, comprising i) 10-100000 IU/ml of recombinant fador VHI ii) at least 0.01 mg/ml. of a polyoxyethylene (20) fatty add ester iii) sodium chloride, preferably in an amount of more than 0.1 M. iv) calcium salt such as caldum d loride or caldum gluconate preferably in an amount of more than 0.5 mM. v) an amino add such as L-histidine in an amount of more than 1 mM. 15. Composition according to any of daims 1-14 which is dried. 16. Composition according to daim 15 whid is lyophilized. 17. Composition according to any of daims 1-14 which is in a stable aqeous solution ready for use. 18. Composition according to any of claims 3-17 in which the specific activity of r-Vm SQ is more than 12 000 IU / mg protein , preferably more than 14 000 IU / mg. 19. Process for the preparation of the composition according to claim 1 characterized by mixing factor Vπi with a non ionic surfactant in an aqueous solution, preferably together with an amino acid such as L- histidine, sodium salt, sucrose and a caldum salt. 20. Process for the preparation of the composition according to daim 1 characterized by eluating fador Vm from the last purification step with a buffer containing a non-ionic surfactant in an aqeous solution, preferably together with an amino add such as L-histidine, sodium salt, sucrose and a caldum salt. 21. Use of a non ionic surfactant preferably chosen from block co-polymers, - 5 preferably a poloxamer or polyoxyethylene (20) fatty add ester, preferably polysorbate 20 or polysorbate 80, as stabilizer for a composition comprising coagulation factor VHI. 10

Inventors: FATOUROS ANGELICA, OESTERBERG THOMAS, FATOUROS, ANGELICA, OESTERBERG, THOMAS
Applicants: FATOUROS ANGELICA, KABI PHARMACIA AB, OESTERBERG THOMAS
Application year: 1993
Main classification: A61K35
IPC codes: A61K9, A61K35, A61K38, A61K47, C07K14, C12N9